AMCP Summit: Deep Dive Into Prescription Digital Therapeutics

As part of AMCP’s strategic priorities, AMCP will continue to encourage the exchange of ideas among stakeholders and initiate solutions that optimize patients’ health outcomes and address barriers to access to care. As part of this initiative, AMCP is convening a summit to bring together thought leaders to discuss digital therapeutics and share their novel, unique perspectives with managed care professionals.

This Summit was held VIRTUALLY on Thursday, June 1, 2023, from 10am ET to 4pm ET.    

Summit Objectives: 

After attending this Summit, participants should be able to: 

• Explain the role of prescription digital therapeutics and the importance to managed care pharmacy professionals. 

• Describe established practices in evaluating the evidence surrounding digital therapeutics for formulary inclusion. 

• Recognize the unique distribution aspects of prescription digital therapeutics (PDTs) in relation to access to care. 

• Identify the barriers to the adoption of prescription digital therapeutics and possible solutions to address these barriers. 

• Discuss data exchange and security as it relates to prescription digital therapeutics. 

Agenda and Registration: 

Please note that information about this Summit will be updated regularly. 

10–10:15am ET 

Welcome 

Susan A. Cantrell, MHL, RPh, CAE  
Chief Executive Officer  
AMCP  

Summit Moderator: 

Dan Leonard, MA 
Principal
Granite Capitol Consulting

10:15–11am ET 

Digital Therapeutics 101 

What are PDTs compared to digital therapeutics? How are PDTs authorized by the Food and Drug Administration? Discover which products are currently available, where the pipeline is headed, and how digital therapeutics impact managed care pharmacy and ultimately affects patient access and the value of these products. 

Speakers: 

Jeffrey Abraham, MSPT, MBA 
Vice President, Digital Health Practice Co-Lead 
Health Advances 

Allyson Mullen, JD
Director 
Hyman, Phelps & McNamara P.C. 

11am–Noon ET 

Established Practices in Evaluating Data and Formulary Development for Digital Therapeutics 

How are digital therapeutics integrated in managed care organizations for coverage benefits? What are significant differences to consider when reviewing a digital therapeutic compared to a traditional drug? This session will explain the process of how health plans and PBMs address these topics in addition to potential solutions to overcome future challenges that may hinder the managed care organization’s inclusion of this regulated, innovative product. 

Speakers: 

Adam Hoye-Simek, PharmD, RPh 
Senior Pharmacy Manager of Utilization Management 
Devoted Health Plan 

Theresa Juday, RPh 
Director, Specialty Product Development 
CVS Health 

Gail Ryan, PharmD
Director of Pharmaceutical Transformation 
Point32Health 

Mahsa Salsabili, PharmD, PhD
Pharmacoeconomics Specialist 
ForHealth Consulting | UMass Chan Medical School 

Noon–1pm ET 

Break 

1–2:30pm ET 

Operationalizing Prescription Digital Therapeutics: Challenges and Solutions to Adoption 

PDTs carry several challenges when evaluating their application in payment models, some of which include: what changes need to be made to existing compendia and how will health outcomes be monitored? What needs to evolve between the patient and sponsor relationship to enable pharmacy reimbursement? Follow the journey from the diagnosis to patient access in this session that will describe the areas of success and opportunity related to PDTs. 

Speakers: 

Edward Cox
General Manager & Head, Pfizer Digital Health & Medicines 
Pfizer, Inc. 

Ann Johnson, PharmD
President 
Pharmacy Healthcare Solutions, LLC 

Rob O’Brien, RPh
Senior Vice President, Specialty Pharmacy 
Real Endpoints 

Benjamin Parcher, PharmD, MS
Global Market Access Lead, CNS Digital Therapeutics 
Boehringer Ingelheim Pharmaceuticals, Inc. 

Scott Whittle, MD
Chief Medical Officer 
Meridian Outcomes 

2:30–2:45pm ET 

Break 

2:45-3:45pm ET 

Prescription Digital Therapeutics Data Exchange and Security 

What components of PDT data exchange are important for managed care organizations to be aware of? How do payers evaluate adherence or engagement and what data security guidelines are available? Key components of PDTs will be discussed involving data exchange and security, including encryption, infrastructure, and certification. 

Speakers: 

Titi Ala’ilima, MSE 
VP Applied Data 
Akili Interactive Labs, Inc.

C. Lucas Beal, JD 
Partner 
Hutchison, PLLC 

Jessilyn Dunn, PhD
Assistant Professor 
Duke University 

David Putrino, PhD, PT  
Professor 
Icahn School of Medicine at Mount Sinai 

3:45–4pm ET 

Wrap-Up 

What have you learned regarding digital therapeutics and its future? What gains have been and what challenges still exist in anticipation of the evolving pipeline? Join us in the closing of the AMCP Summit: Deep Dive into Prescription Digital Therapeutics!  

AMCP Registration Fees: 

• AMCP Member: Free 
• Non-Member: $125

Sponsors

Thank you to the sponsors of AMCP Summit: Deep Dive Into Prescription Digital Therapeutics.